Management of methicillin-resistant Staphylococcus aureus pneumonia

Current Opinion in Infectious Diseases

Volumn 23, Issue 2, 2010, Pages 178-184

  Luna, Carlos M ^a   Boyeras Navarro, Iris D ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Community acquired pneumonia; Healthcare associatedpneumonia; Hospital acquired pneumonia; Management; Methicillin resistant Staphylococcus aureus; Pneumonia,ventilator associated pneumonia

Indexed keywords

7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; 7BETA [2 (5 AMINO 1,2,4 THIADIAZOL 3 YL) 2 ETHOXYIMINOACETAMIDO] 3 [(1 METHYLAMINOPROPYL 1H IMIDAZO[4,5 B]PYRIDINIUM 4 YL)METHYL] 3 CEPHEM 4 CARBOXYLIC ACID; CB 181963; CEFTOBIPROLE; CEPHALOSPORIN; DALBAVANCIN; LB 11058; LINEZOLID; ORITAVANCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN; WCK 771;

DRUG TREATMENT FAILURE; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; PHARMACODYNAMICS; REVIEW; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; VANCOMYCIN;

EID: 77649254592     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328336a23f     Document Type: Review

References (61)

1. Yok-Al Q, Moreillon P. Staphylococcus aureus (including staphylococcal toxic shock) in PART III. Infectious diseases and their etiologic agents. Mandell, Douglas and Bennett's principles and practice of infectious diseases, 7th ed. Churchill Livingstone, An Imprint of Elsevier. 2009.
2. Chambers HF, Hartman BJ,Tomasz A. Increased amounts of a novel penicillin binding protein in a strain of methicillin-resistant Staphylococcus aureus. J Clin Invest 2005; 76:325-331.
3. Klevens RM, Edwards JR, Tenover FC, etal. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-391.
4. Guzman-Blanco M, Mej́ia C, Isturiz R, et al. Epidemiology of methicillinresistant Staphylococcus aureus (MRSA) in Latin America. Int J Antimicrob Agents 2009; 34:304-308.
5. Moran GJ, Krishnadasan A, Gorwitz RJ, etal. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-674.
6. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-59.
7. Shorr AF. Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007; 25:751-768.
8. Zetola N, Francis JS, Nuermberger EL, et al. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005; 5:275-286.
9. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of healthcare-associated pneumonia. Results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-3862.
10. Panlilio AL, Culver DH, Gaynes RP, etal. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992; 13:582-586.
11. Diekema DJ, Pfaller MA, Schmitz FJ, et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S114-S132.
12. Klevens RM, Morrison MA, Nadle J, etal. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-1771.
13. Vardakas KZ, Matthaiou DK, Falagas ME. Incidence, characteristics and outcomes of patients with severe CA-MRSA pneumonia. Eur Resp J 2009; 34:1148-1158.
14. Ito T, Katayama Y, Asada K, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:1323-1336.
15. Ito T OK, Ma XX, et al. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC. Drug Resist Update 2003; 6:41-52.
16. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147-1152.
17. Arnold FW, Summersgill JT, Lajoie AS, et al. Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086-1093.
18. Baba T, Takeuchi F, Kuroda M, et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359:181 9-1827.
19. Couto I, de Lencastre H, Severina E, et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb Drug Resist 1996; 2:377-391.
20. Shorr AF, Tabak YP, Gupta V, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care 2006; 10:R97.
21. Luna CM, Monteverde A, Rodŕiguez A, et al. Clinical guidelines for the treatment of nosocomial pneumonia in Latin America: an interdisciplinary consensus document. Recommendations of the Latin American Thoracic Society. Arch Bronconeumol 2005; 41:439-456.
22. Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171-1175.
23. IwaharaT, IchiyamaS, NadaT, etal. Clinical and epidemiologic investigations of nosocomial pulmonary infections caused by methicillin- resistant Staphylococcus aureus. Chest 1994; 5:826-831.
24. Mizell KN, Patterson KV, Carter JE. Empyema necessitatis due to methicillin-resistant Staphylococcus aureus: case report and review of the literature. J Clin Microbiol 2008; 46:3534-3536.
25. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008; 31:625-632.
26. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333-339.
27. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and resistant Staphylococcus aureus infections. Ann Pharmac-other 2004; 38:1377-1382.
28. Stryjewski ME, Szczech LA, Benjamin DK Jr, etal. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-196.
29. Neofytos D, Kuhn B, Shen S, et al. Emergence of staphylococcal cassette chromosome mec type IV methicillin-resistant Staphylococcus aureus as a cause of ventilator-associated pneumonia. Infect Control Hosp Epidemiol 2007; 28:1206-1209.
30. Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza: Louisiana and Georgia, 2006-2007. MMWR Morb Mortal Wkly Rep 2007; 56:325-329.
31. Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus communityacquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009; 53:1358-1367.
32. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36:131-139.
33. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, et al. Panton Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198:1166-1170.
34. Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valantine leukocidin causes necrotizing pneumonia. Science 2007; 315.
35. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685.
36. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-420.
37. Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
38. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27-S72.
39. Vidaur L, Planas K, Sierra R, et al. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest 2008; 133:625-632.
40. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infection. Int J Antimicrob Agents 2000; 16:S31-S34.
41. Chastre J, Wolff M, Fagon J-Y, etal. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults, a randomized trial. JAMA 2003; 290:2588-2598.
42. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparision of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150:1545-1549.
43. Tacconelli E, Cataldo MA. Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opin Pharmacother 2007; 8:2505-251 8.
44. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398-2402.
45. Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700-1705.
46. Jeffres MN, Isakow W, Doherty JA, etal. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-955.
47. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003; 26:876-879.
48. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006; 26:539-550.
49. Pea F, Viale P. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008; 47:147-152.
50. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005; 33:1529-1533. (Pubitemid 40980608)
51. Luna CM, Bruno D, Garćia Morato J, et al. Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneu monia in piglets. Chest 2009; 135:1564-1571.
52. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. dcHEST 2003; 124: 1789-1797.
53. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiologic response to linezolid versus vancomycin in ventilator-associated pneumonia (VAP) due to methicillin-resistant Staphylococcus aureus (MRSA). Chest 2008; 134:1200-1207.
54. Maclayton DO, Hall RG 2nd. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007; 41:235-244.
55. MacGowan AP. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008; 62 (Suppl 1):i11-i16.
56. Zhanel GG, Lam A, Schweizer F, et al. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 2008; 9:245-254.
57. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46:S378-S385.
58. Gauduchon V, Cozon G, Vandenesch F, et al. Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 2004; 189:346-353.
59. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287-294.
60. Masterton RG, Galloway A, French G, etal. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. Antimicrob Chemother 2008; 62:5-34.
61. Kollef MH, Micek ST. Methicillin-resistant Staphylococcus aureus: a new community acquired pathogen? Curr Opin Infect Dis 2006; 19: 161-168.